Sepsis & infection

The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections

Intensive Care MedPublished Secondary analysis of the EUROBACT-2 prospective cohort study

An erratum to this article was published (Intensive Care Med, Jun 2024 ↗)

Study context

Population
ICU patients with hospital-acquired bloodstream infections (HABSI)
Participants
2,209 patients · 201 intensive care units (ICUs) · 47 countries
Comparison
Centre/country-based factors and adequate antimicrobial therapy and 28-day mortality
Primary endpoint
Associations between centre/country-based factors and two process and outcome indicators: adequacy of antimicrobial therapy within the first 24 h and 28-day mortality
Methodological detailsmultinational, mixed logistic models clustered by centre
  • Multinational
  • Mixed logistic models clustered by centre

Primary result

As reported in the abstract

Adequate antimicrobial therapy, overall
51% (n = 1128)
28-day mortality, overall
38% (n = 839)
Adequate therapy: Therapeutic drug monitoring (TDM) for aminoglycosides everyday, OR
1.48 (1.03-2.14) (95% CI)
Adequate therapy: TDM for aminoglycosides within a few hours, OR
1.79 (1.34-2.38) (95% CI)
Adequate therapy: weekly surveillance cultures for multidrug-resistant organism carriage, OR
1.45 (1.09-1.93) (95% CI)
28-day mortality: intermediate care beds, OR
0.63 (0.47-0.84) (95% CI)
28-day mortality: TDM for aminoglycoside available everyday, OR
0.66 (0.44-1.00) (95% CI)
28-day mortality: TDM for aminoglycoside within a few hours, OR
0.51 (0.37-0.70) (95% CI)
28-day mortality: 24/7 consultation of clinical pharmacists, OR
0.67 (0.47-0.95) (95% CI)
28-day mortality: Vancomycin-resistant enterococci (VRE) 10% to 25% in the ICU, OR
1.67 (1.00-2.80) (95% CI)

Original publication

The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections. Intensive Care Med. Published 18 March 2024. doi:10.1007/s00134-024-07348-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.